Skip to content

Editas Medicine, Inc.

EDIT· NasdaqCore metricsCIK 1650664

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -10.29%
Market cap
$329.52M
154.34M shares
Filings
733
$10.37M
Q3 2026+25.4% FY25 yoy
-$23.39M
Q3 2026N/M FY25 yoy
-$24.28M
Q3 2026N/M FY25 yoy
-$74.02M
Q3 2026derivedN/M FY25 yoy
-$0.15
Q3 2026N/M FY25 yoy
$93.17M
Q3 2026+11.5% FY25 yoy
$329.52M
—
6.6×
3.9×
-33.52%
—

Twelve months to Sep 30, 2026 · derived

Price

$2.1419.74%$0.53past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$40.52MFY 2025
$90.73M0FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$40,520,000reported
FY 20242024-12-31$32,314,000reported
FY 20232023-12-31$78,123,000reported
FY 20222022-12-31$19,712,000reported
FY 20212021-12-31$25,544,000reported
FY 20202020-12-31$90,732,000reported
FY 20192019-12-31$20,531,000reported
FY 20182018-12-31$31,937,000reported
FY 20172017-12-31$13,728,000reported
FY 20162016-12-31$6,053,000reported

Biological products, except diagnostic substances

Editas Medicine, Inc. is the 46th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR